Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.50 Consensus Target Price from Analysts

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $7.50.

A number of research firms have weighed in on GANX. Oppenheimer reissued an “outperform” rating on shares of Gain Therapeutics in a research note on Wednesday, May 27th. BTIG Research restated a “buy” rating and set a $5.00 price target on shares of Gain Therapeutics in a report on Tuesday. Wall Street Zen upgraded shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. Weiss Ratings downgraded shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Finally, Roth Mkm restated a “buy” rating on shares of Gain Therapeutics in a report on Tuesday, May 12th.

Gain Therapeutics Trading Up 2.5%

GANX opened at $2.03 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.69 and a quick ratio of 4.69. The company’s 50 day simple moving average is $1.82 and its two-hundred day simple moving average is $2.15. Gain Therapeutics has a 1-year low of $1.41 and a 1-year high of $4.34. The firm has a market capitalization of $86.58 million, a price-to-earnings ratio of -3.50 and a beta of 0.16.

Gain Therapeutics (NASDAQ:GANX) last released its earnings results on Monday, May 11th. The company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). During the same quarter in the previous year, the business earned ($0.16) earnings per share. Analysts expect that Gain Therapeutics will post -0.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Gain Therapeutics

A number of hedge funds have recently modified their holdings of the business. Apollon Wealth Management LLC grew its holdings in shares of Gain Therapeutics by 33.7% during the 1st quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock worth $51,000 after purchasing an additional 6,675 shares during the period. Geode Capital Management LLC grew its holdings in shares of Gain Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock worth $523,000 after purchasing an additional 8,251 shares during the period. Sprott Inc. purchased a new position in shares of Gain Therapeutics during the 4th quarter worth $39,000. Commonwealth Equity Services LLC purchased a new position in shares of Gain Therapeutics during the 4th quarter worth $41,000. Finally, Millennium Management LLC purchased a new position in shares of Gain Therapeutics during the 4th quarter worth $45,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.